PDCD1 and neoplasm: The binding of PD-L1 to PD-1 inhibits T cell proliferation and cytokine production, leading to T cell exhaustion and tumor immune evasion, now recognized as one of the hallmarks of cancer and the biological foundation of contemporary immunotherapy [9-11].